Adverse event rates and economic burden associated with purine nucleoside analogs in patients with hairy cell leukemia: a US population-retrospective claims analysis

BACKGROUND: Purine nucleoside analogs (PNAs) are the recommended first-line treatment for patients with hairy cell leukemia (HCL), but they are associated with adverse events (AEs). Due to a lack of real-world evidence regarding AEs that are associated with PNAs, we used commercial data to assess AE...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Orphanet J Rare Dis
Hlavní autoři: Epperla, Narendranath, Pavilack, Melissa, Olufade, Temitope, Bashyal, Richa, Li, Jieni, Kabadi, Shaum M., Yuce, Huseyin, Andritsos, Leslie
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2020
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7020358/
https://ncbi.nlm.nih.gov/pubmed/32054500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-020-1325-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky